# Prolonged Enoxaparin in Primary Percutaneous Coronary Intervention

Study · id `cardio:ct-nct03568838` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03568838](<https://clinicaltrials.gov/study/NCT03568838>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03568838

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 100 participants.

## Technical summary

Registry record NCT03568838. Randomized; no masking; primary purpose prevention. Start 2018-06-28 (actual); primary completion 2020-05-01 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose prevention
- Phase: Phase 4
- Enrolled: 100 participants (enrolled count; ClinicalTrials.gov record NCT03568838, source copy `cardio:ctgov-nct03568838-2022-11-15`, retrieved 2026-10-26)
- Started: 2018-06-28 (actual) (ClinicalTrials.gov record NCT03568838, source copy `cardio:ctgov-nct03568838-2022-11-15`, retrieved 2026-10-26)
- Primary completion: 2020-05-01 (actual) (ClinicalTrials.gov record NCT03568838, source copy `cardio:ctgov-nct03568838-2022-11-15`, retrieved 2026-10-26)
- Completion: 2020-05-01 (actual) (ClinicalTrials.gov record NCT03568838, source copy `cardio:ctgov-nct03568838-2022-11-15`, retrieved 2026-10-26)
- Countries: United Kingdom (ClinicalTrials.gov record NCT03568838, source copy `cardio:ctgov-nct03568838-2022-11-15`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03568838-2022-11-15`, retrieved 2026-10-26)

## The registry's words

- Brief title: Prolonged Enoxaparin in Primary Percutaneous Coronary Intervention
- Acronym: PENNYWISE
- Condition: Myocardial Infarction
- Intervention (Drug): Enoxaparin
- Lead sponsor: Sheffield Teaching Hospitals NHS Foundation Trust
- Lead sponsor class: OTHER
- Collaborator: Medical Research Council
- Collaborator class: OTHER\_GOV

## Connected pages

- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry intervention name matches this record: Enoxaparin (`core:enoxaparin`)
- Registry lists this organization as the lead sponsor: Sheffield Teaching Hospitals NHS Foundation Trust (`cardio:org-sheffield-teaching-hospitals-nhs-foundation-trust`)
- Registry lists this organization as a collaborator: Medical Research Council (United Kingdom) (`cardio:mrc`)

## Provenance

Content hash: dcb6fbe4a9547b9857764af426d752394091601c56d5132bf23ab8d9b7d9a1de
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
